Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Ocuphire Pharma (OCUP) has issued an announcement.
Ocuphire Pharma, Inc. has engaged board director Dr. Jay Pepose as a consultant, compensating him with a monthly fee of $39,583, 32,000 restricted stock units, and options for 48,000 shares at $1.79 each. These incentives will vest over a year, incentivizing Dr. Pepose’s continued involvement with the company until the Consulting Agreement’s end date of April 11, 2025, signaling strategic moves that may interest stock market enthusiasts.
For an in-depth examination of OCUP stock, go to TipRanks’ Stock Analysis page.